Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety

by Yanming Wang, Lianqi Liu, Shiyong Fan, Dian Xiao, Fei Xie, Wei Li, Wu Zhong, Xinbo Zhou
Published 2020-03-01

Estimering av GPS pålitlighet och GPS/INS fusion

by Johansson, Mattias
Published 2013

Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells

by Falgàs A, Pallarès V, Unzueta U, Núñez Y, Sierra J, Gallardo A, Alba-Castellón L, Mangues MA, Álamo P, Villaverde A, Vázquez E, Mangues R, Casanova I
Published 2021-03-01

PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

by Qiyu Li, Wenjing Li, Keyuan Xu, Yutong Xing, Haobo Shi, Zhe Jing, Shuang Li, Zhangyong Hong
Published 2021-02-01

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

by Tero Satomaa, Henna Pynnönen, Anja Vilkman, Titta Kotiranta, Virve Pitkänen, Annamari Heiskanen, Bram Herpers, Leo S. Price, Jari Helin, Juhani Saarinen
Published 2018-03-01

Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer

by Htoo Zarni Oo, Zoltan Lohinai, Nastaran Khazamipour, Joey Lo, Gunjan Kumar, Jessica Pihl, Hans Adomat, Noushin Nabavi, Hakhamanesh Behmanesh, Beibei Zhai, Robert Dagil, Swati Choudhary, Tobias Gustavsson, Thomas M. Clausen, Jeffrey D. Esko, Jeffrey W. Allen, Michael A. Thompson, Nhan L. Tran, Judit Moldvay, Balazs Dome, Ali Salanti, Nader Al-Nakouzi, Glen J. Weiss, Mads Daugaard
Published 2021-09-01

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

by Anna M. Serwotka-Suszczak, Alicja M. Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, Jacek Otlewski
Published 2017-02-01

An EGFR‐targeting antibody–drug conjugate LR004‐VC‐MMAE: potential in esophageal squamous cell carcinoma and other malignancies

by Xin‐yue Hu, Rong Wang, Jie Jin, Xiu‐jun Liu, A‐long Cui, Lian‐qi Sun, Yan‐ping Li, Yi Li, Yu‐cheng Wang, Yong‐su Zhen, Qing‐fang Miao, Zhuo‐rong Li
Published 2019-02-01

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma

by Makita S, Maruyama D, Tobinai K
Published 2020-06-01

Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer

by Xinning Wang, Aditi Shirke, Ethan Walker, Rongcan Sun, Gopolakrishnan Ramamurthy, Jing Wang, Lingpeng Shan, Joey Mangadlao, Zhipeng Dong, Jing Li, Ziying Wang, Mark Schluchter, Dong Luo, Yu Wang, Shaun Stauffer, Susann Brady-Kalnay, Christopher Hoimes, Zhenghong Lee, James P. Basilion
Published 2021-01-01

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1

by Alicja M. Sochaj-Gregorczyk, Patryk Ludzia, Emilia Kozdrowska, Piotr Jakimowicz, Aleksandra Sokolowska-Wedzina, Jacek Otlewski
Published 2017-08-01

Electrochemical Model-Based Condition Monitoring via Experimentally Identified Li-Ion Battery Model and HPPC

by Md Ashiqur Rahman, Sohel Anwar, Afshin Izadian
Published 2017-08-01

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs

by Aman P. Singh, Leiming Guo, Ashwni Verma, Gloria Gao-Li Wong, Dhaval K. Shah
Published 2019-02-01

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)

by Hsuan Ping Chang, Yuen Kiu Cheung, Dhaval K. Shah
Published 2021-03-01

Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY^®) Antibody–Drug Conjugate in Sprague Dawley Rats

by Victor Yip, M. Violet Lee, Ola M. Saad, Shuguang Ma, S. Cyrus Khojasteh, Ben-Quan Shen
Published 2021-03-01

Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles

by Esteban Cruz, Veysel Kayser
Published 2019-06-01

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

by Gabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Published 2019-03-01

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

by Efrat T. Harel, Penelope M. Drake, Robyn M. Barfield, Irene Lui, Shauna Farr-Jones, Laura Van’t Veer, Zev J. Gartner, Evan M. Green, André Luiz Lourenço, Yifan Cheng, Byron C. Hann, David Rabuka, Charles S. Craik
Published 2019-11-01

Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells

by Woitok M, Klose D, Di Fiore S, Richter W, Stein C, Gresch G, Grieger E, Barth S, Fischer R, Kolberg K, Niesen J
Published 2017-07-01

Delivery of Potent Anti-Mitotic Chemotherapeutic Using High Aspect Ratio, Soft Matter Nanoparticles

by Kernan, Daniel L.
Published 2016